Alogliptin: a new addition to the class of DPP-4 inhibitors
Radha Andukuri, Andjela Drincic, Marc RendellDivision of Endocrinology, Department of Medicine, Creighton University School of Medicine, Omaha, Nebraska, USABackground: Alogliptin is an oral antihyperglycemic agent that is a selective inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). Inhibitio...
Guardado en:
Autores principales: | Radha Andukuri, Andjela Drincic, Marc Rendell |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3735030292114be3af9d5fe5b144b38a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects
por: Kapoor S
Publicado: (2012) -
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
por: Kishimoto M
Publicado: (2013) -
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes
por: Gallwitz B
Publicado: (2013) -
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Bo Ahrén
Publicado: (2010) -
Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin
por: Russo E, et al.
Publicado: (2013)